Immune Cell Therapy with mRNA-LNP
Figure 1. Overview of pre-clinical cell therapy development with mRNA-LNP technology, starting from antibody engineering, mRNA encapsulation, immune cell transfection & expansion, and it's potential for clinical application.
We can validate the positive cells with many different functional assays
K562 Transfected with GFP-LNP
Figure 2. Fluorescent imaging of K562 cells, before and after transfection with GFP+ mRNA-LNP.
HEK293S Transfected with GFP-LNP and Stability Test
Figure 3. Expression of GFP-LNP in HEK293S cells and their stability. Freeze-thaw cycles of HEK293S cells transfected with ProMab mRNA delivered via ProMab lipid nanoparticles. Flow cytometry measurement after 1 thawing cycle, and 24 hours at -80°C
We can deliver mRNA-LNP to immune cells
GFP+ mRNA-LNP Delivery and Expression in T Cells
Figure 4. Left: High expression of GFP measured by flow cytometry 72 hours after adding GFP+ mRNA-LNP. Right: High cell viability measured by trypan blue cell counting.
CAR+ mRNA-LNP Delivery and Expression in NK Cells
Figure 5. ProMab mRNA-LNP Nanoparticle with chimeric antigen receptor (CAR) mRNA generated CAR-NK cells. Left: Non-transfected NK cell control. Right: NK cell + LNP-CAR formulation.
CAR+ mRNA-LNP Delivery and Expression in T Cells
Figure 6. ProMab mRNA-LNP Nanoparticle with chimeric antigen receptor (CAR) mRNA generated CAR-T cells. Left: Non-transfected T cell control. Middle: T cell + LNP-CAR formulation by mouse Fab-APC. Right: T cell + LNP-CAR formulation, detected by mouse Fab-FITC.
ProMab BCMA-CAR T cells kill target cells in 24 hours after RNA CAR-LNP introduction
Figure 7. Left: BCMA CAR-T cytotoxicity measured by real-time cytotoxicity assay (RTCA). Right: Cytokine secretion measurement by IFN-gamma ELISA.